FAR Biotech expands to Madison: What this means for AI-based drug development
FAR Biotech brings its QuantumAI platform to Madison. Find out what this move means for drug discovery, platform scalability, and Wisconsin’s biohealth future.
iRegene’s NouvNeu001 becomes first iPSC therapy with RMAT and Fast Track designations
Find out how iRegene’s iPSC-based Parkinson’s therapy NouvNeu001 became the first to earn both RMAT and Fast Track status from the FDA.
Can Amneal’s Parkinson’s strategy evolve beyond symptoms? KeifeRx tie-up may signal shift
KeifeRx and Amneal join forces on KFRX06, a brain-penetrant LRRK2 inhibitor for Parkinson’s. Find out what this could mean for CNS innovation.
QurAlis links QRL-101 to motor nerve excitability shift in ALS: Is target validation finally here?
QurAlis confirms target engagement of QRL-101 in ALS patients. Find out what this means for epilepsy trials and Kv7-targeted drug development.
Meta-Flux and Mercury Bio team up to target intracellular CNS pathways with precision
Mercury Bio Inc., a biotechnology company focused on large-molecule therapeutics, has announced a strategic collaboration with Meta-Flux, a disease simulation company that leverages artificial intelligence, to advance drug discovery programs for Parkinson’s disease and Alzheimer’s disease. The partnership combines Mercury Bio’s proprietary yeast extracellular vesicle (yEV) delivery technology with Meta-Flux’s disease-scale computational modeling platform, with […]
What makes Prilenia’s PREVAiLS trial different from past ALS failures
FDA clears Prilenia’s PREVAiLS ALS trial. Can pridopidine validate neuroprotection and shift the treatment paradigm? Read the full analysis here.